← back to search

Christopher G. Kanakry

National Institutes of Health · US
Area of research
Hematology · Immunology
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Immune Cell Function and Interaction, T-cell and B-cell Immunology, and Acute Lymphoblastic Leukemia research.
h-index
33
citations
5,127
works
165
NIH funding
primary concept
Medicine
email

Recent publications

Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations
Transplantation and Cellular Therapy 2025cited by 7position: middledoi
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR
Blood Advances 2025cited by 6position: middledoi
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
Blood Advances 2023cited by 24position: middledoi
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis
Blood 2021cited by 174position: middledoi
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis
Blood 2021cited by 162position: middledoi
Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning
Blood 2021cited by 98position: middledoi
Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome
Transplantation and Cellular Therapy 2021cited by 42position: middledoi
Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults
Transplantation and Cellular Therapy 2021cited by 29position: middledoi
Incidence and impact of community respiratory viral infections in post‐transplant cyclophosphamide‐based graft‐<i>versus</i>‐host disease prophylaxis and haploidentical stem cell transplantation
British Journal of Haematology 2021cited by 27position: middledoi
An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
Bone Marrow Transplantation 2021cited by 26position: middledoi
Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation 2021cited by 20position: middledoi
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission
Blood Advances 2019cited by 128position: middledoi
Short telomere syndromes cause a primary T cell immunodeficiency
Journal of Clinical Investigation 2018cited by 122position: middledoi
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Haematologica 2017cited by 282position: middledoi
Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia
Biology of Blood and Marrow Transplantation 2017cited by 97position: middledoi
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide
Haematologica 2016cited by 187position: middledoi
Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide
JCI Insight 2016cited by 144position: firstdoi
Modern approaches to HLA-haploidentical blood or marrow transplantation
Nature Reviews Clinical Oncology 2015cited by 327position: firstdoi
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
Blood 2015cited by 299position: middledoi
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS
Blood 2014cited by 198position: firstdoi
Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice
Blood 2014cited by 195position: middledoi
Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation Cyclophosphamide
Science Translational Medicine 2013cited by 356position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Leo Luznik · U-M Rogel Cancer Center7 papers (2013–2021)Richard J. Jones · University College London4 papers (2013–2021)Ephraim J. Fuchs · U-M Rogel Cancer Center4 papers (2013–2016)Javier Bolaños‐Meade · Comprehensive Blood & Cancer Center3 papers (2013–2016)Jennifer A. Kanakry · Cancer Institute (WIA)3 papers (2014–2025)Robert A. Brodsky · Sidney Kimmel Cancer Center2 papers (2014–2016)Carol Ann Huff · Johns Hopkins University2 papers (2014–2016)Mark J. Levis · University of Turin2 papers (2014–2016)Margaret M. Showel · National Heart Lung and Blood Institute2 papers (2014–2016)Hua‐Ling Tsai · Johns Hopkins University2 papers (2014–2016)Lode J. Swinnen · Tokyo National Hospital2 papers (2014–2016)Douglas E. Gladstone · Northwell Health2 papers (2014–2016)Gary L. Rosner · United States Food and Drug Administration2 papers (2014–2016)Heather J. Symons · Pediatric Oncology Group2 papers (2016–2021)B. Douglas Smith · University of Rochester Medical Center2 papers (2014–2016)William Matsui · The University of Texas at Austin2 papers (2014–2016)Jonathan D. Powell · Johns Hopkins Medicine2 papers (2014–2021)Ivan Borrello · Johns Hopkins Medicine2 papers (2014–2016)Amy E. DeZern · U-M Rogel Cancer Center2 papers (2014–2016)Keith W. Pratz · Abramson Cancer Center2 papers (2014–2016)